The NCI-MATCH trial: lessons for precision oncology
Abstract The NCI-MATCH (Molecular Analysis for Therapy Choice) trial (NCT02465060) was
launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial …
launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial …
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
G Liu, T Chen, Z Ding, Y Wang, Y Wei, X Wei - Cell proliferation, 2021 - Wiley Online Library
The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large
multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid …
multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid …
Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders
Personalized medicine aims to match the right drug with the right patient by using specific
features of the individual patient's tumor. However, current strategies of personalized …
features of the individual patient's tumor. However, current strategies of personalized …
Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response
Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-
adapted based on clinical features, leukemia genomics and minimal residual disease …
adapted based on clinical features, leukemia genomics and minimal residual disease …
[HTML][HTML] Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast
growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer. However …
growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer. However …
FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention
A De Luca, R Esposito Abate, AM Rachiglio… - International journal of …, 2020 - mdpi.com
Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors involved in many
biological processes. Deregulated FGFR signaling plays an important role in tumor …
biological processes. Deregulated FGFR signaling plays an important role in tumor …
Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer
C Francavilla, CS O'Brien - Open Biology, 2022 - royalsocietypublishing.org
Fibroblast Growth Factor Receptor (FGFR) signalling plays a critical role in breast embryonal
development, tissue homeostasis, tumorigenesis and metastasis. FGFR, its numerous FGF …
development, tissue homeostasis, tumorigenesis and metastasis. FGFR, its numerous FGF …
The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies
The altered activation or overexpression of protein kinases (PKs) is a major subject of
research in oncology and their inhibition using small molecules, protein kinases inhibitors …
research in oncology and their inhibition using small molecules, protein kinases inhibitors …
National cancer institute combination therapy platform trial with molecular analysis for therapy choice (ComboMATCH)
Over the past decade, multiple trials, including the precision medicine trial National Cancer
Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) …
Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) …